https://www.cerebralpalsyguide.com/community/special-education/
Parent Corner
The FASD Social Laboratory
2023 FASD Social Lab Summary
Interventions For Children With Prenatal Exposures
FASDHawaii.org 2023 Day @ the Capital – Ann & Ken Yabusaki, Founders, Alan Shinn, Director
FASDHawaii.org raising awareness at the Hawai’i State Capital on March 2, 2023.
Parent & Caregiver Support Group
FASDHawaii.org Parent & Caregiver Support Group Meetings held quarterly in 2023. Facilitated by: Sina P. Pili
Drug addiction, or substance use disorder (SUD), affects millions of people in the United States each year. Understanding the causes and consequences of the cycle of addiction is the first step toward recovery.
Families Moving Forward (FMF) Connect Study – FASD Research
University of Rochester Medical Center seeking children 3 to 12 yrs. diagnosed with FASD or known prenatal alcohol exposure to participate in a research study. Study includes the use of an app and monetary compensation.
Parent & Caregiver Support Group (Free Zoom Meeting Quarterly 2022)
Quarterly meeting for parents and caregivers of a person living with FASD
Individual with Disabilities Education Act (IDEA) Provision of Services – COVID 19-Resources & Information
Part C Provision of Services in the COVID-19 Environment Q&A Document (Oct. 20, 2020)
Addresses inquiries concerning implementation of the Individuals with Disabilities Education Act (IDEA) Part C provision of service in the current COVID-19 environment.
Experts publish the first medication guidelines for people with FASD
https://canfasdblog.com/2020/09/28/canadian-experts-publish-the-first-medication-guidelines-for-people-with-fasd/A team of experts from across Canada and the US have developed the first ever medication algorithm for individuals with Fetal Alcohol Spectrum Disorder (FASD). CanFASD Research Leads Dr.’s Mansfield Mela and Ana Hanlon-Dearman and CanFASD Family Advisory Committee’s Dorothy Reid are among the co-authors of the study. This algorithm is now an important tool available for clinicians to use to treat individuals with FASD (children and adolescents aged 7 and above, and adults).